Investors Purchase Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) saw unusually large options trading on Tuesday. Stock traders bought 13,044 call options on the company. This represents an increase of 748% compared to the typical daily volume of 1,538 call options.

Analysts Set New Price Targets

A number of research firms have issued reports on CAPR. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 price target on shares of Capricor Therapeutics in a research report on Friday, September 20th. Maxim Group lifted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, September 24th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $22.60.

Capricor Therapeutics Stock Up 10.1 %

CAPR opened at $16.52 on Thursday. Capricor Therapeutics has a 52 week low of $2.68 and a 52 week high of $18.14. The business has a 50 day moving average price of $5.21 and a two-hundred day moving average price of $5.42. The company has a market cap of $528.29 million, a PE ratio of -18.99 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The firm had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. As a group, sell-side analysts expect that Capricor Therapeutics will post -1.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 12.00% of the stock is owned by insiders.

Institutional Trading of Capricor Therapeutics

A number of institutional investors have recently modified their holdings of CAPR. BNP Paribas Financial Markets purchased a new stake in shares of Capricor Therapeutics during the 1st quarter worth $40,000. Main Street Financial Solutions LLC lifted its stake in shares of Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the period. Rhumbline Advisers purchased a new stake in Capricor Therapeutics during the second quarter worth about $147,000. Bank of New York Mellon Corp grew its position in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares during the period. Finally, Marshall Wace LLP purchased a new position in Capricor Therapeutics in the second quarter valued at about $426,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.